ReviewCurrent rheumatology reports2005
The use of anakinra in juvenile arthritis.
Review in Current rheumatology reports, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence.Clinical rheumatology · 2008Pooled it
- Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment.Biologics in therapy · 2012Review
- Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states.Clinical immunology (Orlando, Fla.) · 2010Article
- Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses.The Journal of allergy and clinical immunology · 2009Review
- Blocking interleukin-1 in rheumatic diseases.Annals of the New York Academy of Sciences · 2009Article
- Challenges in the management of juvenile idiopathic arthritis with etanercept.Biologics : targets & therapy · 2009Article
- Cytokines secreted in response to Toll-like receptor ligand stimulation modulate differentiation of human Th17 cells.Arthritis and rheumatism · 2008Article
- Advances in the diagnosis and immunotherapy for ocular inflammatory disease.Seminars in immunopathology · 2008Review
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.Annals of the rheumatic diseases · 2007Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-1 (IL-1), one of the major pro-inflammatory cytokines, plays an important role in the pathophysiology and progression of adult and pediatric arthritis. Inhibiting IL-1 activity by using a recombinant human IL-1 receptor antagonist (anakinra) given alone or in combination with methotrexate, moderately reduced the signs and symptoms of active arthritis in adults and slowed the rate of radiographic destruction. Preliminary results from an open label portion of a trial in children with polyarticular arthritis show similar outcomes with 58% of children exhibiting clinical improvements based on the Juvenile Arthritis 30% Core Set Criteria. The drug has an overall favorable safety profile and injection-site reactions are the most commonly reported adverse event in both groups. However despite its rather disappointing effect in polyarticular arthritis, anakinra is being discovered as an effective treatment of systemic arthritis and children with mutations in the NALP3/CIAS1/PYPAF1 genes leading to autoimmune inflammatory disorders such as neonatal- onset multisystem inflammatory disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.